1-(3-氯苯基)-2-羟基-2-[(8-羟基喹啉-7-基)氨基]乙酮 | 54879-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-氯苯基)-2-羟基-2-[(8-羟基喹啉-7-基)氨基]乙酮
• 英文名称: N-benzyl-2,2-dimethoxyethylamine
• 英文别名: N-benzyl-2,2-dimethoxyethanamine；benzylaminoacetaldehyde dimethyl acetal；N-benzyl-2,2-dimethoxyethan-1-amine
• CAS: 54879-88-8
• 化学式: C₁₁H₁₇NO₂
• mdl: MFCD00963826
• 分子量: 195.261
• InChiKey: LODLUMZUJRFPLU-UHFFFAOYSA-N

物化性质

• 沸点：
  102 °C(Press: 1 Torr)
• 密度：
  1.008±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922199090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存于室温、避光环境中，并在惰性气氛下保存。

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-2-羟基-2-[(8-羟基喹啉-7-基)氨基]乙酮 在 硫酸 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.25h， 生成 methyl (1R,5S,7R)-3-benzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-exo-carboxylate
  参考文献：
  名称：

  Synthesis and Reactivity of Bicycles Derived from Tartaric Acid and α-Amino Acids:  A Novel Class of Conformationally Constrained Dipeptide Isosteres Based upon Enantiopure 3-Aza-6,8-dioxabicyclo[3.2.1]octane-7-carboxylic Acid

  摘要：

  3-Aza-6,8-dioxabicyclo[3.2.1]octane-7-carboxylic acids (named BTAa) derived from (R,R), (S,S)-, or meso-tartaric acid and natural (L), unnatural (D), or unusual alpha-amino acids are described as conformationally constrained dipeptide isosteres. The general strategy developed for their preparation has required the transformation of the amino acids into the corresponding N-benzylamino alcohols, followed by the PyBroP-promoted condensation with the monomethyl ester of the suitable 2,3-di-O-isopropylidenetartaric acid. Oxidation of the hydroxy group to aldheyde and subsequent acid-catalyzed trans-acetalization with the two hydroxy groups of the tartaric acid moiety provided 3-aza-2-oxo-6,8-dioxabicyclo [3.2.1] octane-7-carboxylic acid methyl esters [named BTAa(O)] in good yield and, in most cases, as single enantiopure diastereoisomers. This strategy has been applied to the preparation of BTAa(O) starting from (R,R)-, (S,S)-, or meso-tartaric acid and glycine, L- and D-phenylalanine, L- and D-alanine, and (+/-)-phenylglycine. In the cases of glycine, L- and D-phenylalanine, and L- and D-alanine, the selective reduction by BH3. DMS of the amide group succeeding to the cyclization step, or the reduction of both amide and ester functions followed by reoxidation of the hydroxy to carboxylic group, provided in good yield the 3-aza-3-benzyl-6,8-dioxabicyclo[3.2.1]-octane-7-carboxylic acids (or their methyl ester) BTAa, having the side chain of the amino acid precursors at position 4. The stability and rigidity of the bicyclic skeleton, the complete control of all the stereocenters, the possibility of introducing the side chains of L- or D-amino acids, and the demonstrated compatibility with the conditions required for solid-phase peptide synthesis make the BTAa compounds potential dipeptide isosteres useful for the synthesis of modified peptides.

  DOI：

  10.1021/jo9904967
• 作为产物：
  描述：

  2-(benzoylamino)acetaldehyde dimethyl acetal 在 硫酸 、 N,N,N,N',N',N'-hexamethyl-1,3-propanediammonium methylsulfate 作用下， 以 甲醇 为溶剂， 以46%的产率得到1-(3-氯苯基)-2-羟基-2-[(8-羟基喹啉-7-基)氨基]乙酮
  参考文献：
  名称：

  芳香酰胺和亚砜的电化学脱氧

  摘要：

  在温和条件下，在铅阴极上实现了多种芳香酰胺的电化学脱氧。在优化的反应条件下，可以耐受缩醛、噻吩基和醚部分。此外, 还原协议可以应用于芳香族和脂肪族亚砜, 以获得相应的硫化物。对于芳香酰胺和亚砜，脱氧反应无需使用昂贵的催化剂或危险的还原剂。由于该过程的高选择性，简单的提取足以将产物与底物分离。简单的净化协议、水的共形成以及使用电流代替还原剂使我们的方法对环境友好且具有经济效益。

  DOI：

  10.1002/ejoc.201402714

文献信息

• Diversity-oriented synthesis of novel polycyclic scaffolds using polymer-bound reagents
  作者：Domingo García-Cuadrado、Sofia Barluenga、Nicolas Winssinger

  DOI：10.1039/b807869f

  日期：——

  A concise sequence utilizing a Petasis three component reaction followed by a tandem aza-Cope–Mannich cyclization afforded novel polycyclic heterocycles in good yield; alternative iminium cyclization based on a Pictet–Spengler reaction or aminal formation led to divergent pathways affording skeletal diversity.

  通过Petasis三组分反应与随后的aza-Cope-Mannich串联环化反应，简洁地合成了产率良好的新型多环杂环化合物；基于Pictet-Spengler反应或氨基醛缩合的亚胺环化提供了不同的途径，导致了骨架多样性。
• [EN] MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES<br/>[FR] PIPERIDINES D'ARYLE OU PIPERAZINES SUBSTITUEES PAR DES HETEROCYCLES A 5 RAMIFICATIONS INHIBANT LA MTP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005085226A1

  公开（公告）日：2005-09-15

  The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper­triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.

  本发明涉及新颖的芳基哌啶或哌嗪化合物，其被某些含有apoB分泌/MTP抑制活性和伴随的降脂活性的5-成员杂环取代。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗高脂血症、肥胖症和2型糖尿病的药物的用途（公式（I））。该发明还涉及制备这种化合物的方法，包括所述化合物的药物组合物以及将所述化合物用作治疗动脉粥样硬化、胰腺炎、肥胖症、高甘油三酯血症、高胆固醇血症、高脂血症、糖尿病和2型糖尿病的药物的用途。
• Design, Synthesis, and Biological Evaluation of Imidazopyrazinone Derivatives as Antagonists of <scp>Inhibitor of Apoptosis Proteins</scp> (IAPs)
  作者：Jisook Kim、Inhwan Bae、Jiyoung Song、Younghoon Kim、Younggil Ahn、Hyun‐Ju Park、Ha Hyung Kim、Dae Kyong Kim

  DOI：10.1002/bkcs.12271

  日期：2021.6

  proteins are overexpressed in many cancers and implicated in tumor growth, so the development of antagonist that disrupts with the binding of IAP to their partner protein is a promising therapeutic strategy. In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized monovalent analogues based on imidazopyrazinone structure of 9. Optimization

  凋亡抑制剂 (IAP) 蛋白在许多癌症中过度表达并与肿瘤生长有关，因此开发可破坏 IAP 与其伙伴蛋白结合的拮抗剂是一种很有前景的治疗策略。为了增加细胞活性并改善有利的类药物特性，我们新设计并合成了基于9咪唑并吡嗪酮结构的单价类似物。细胞效力的优化导致17的鉴定，这表 明亚微摩尔活性 (GI 50 = 234 nM) 和 Caspase-3 激活（6.3 倍）在 MDA-MB-231 乳腺癌细胞中增加。这些发现清楚地表明了17 作为开发有效抗癌治疗的有前途的单价拮抗剂。
• Six-Step Gram-Scale Synthesis of the Human Immunodeficiency Virus Integrase Inhibitor Dolutegravir Sodium
  作者：Jule-Philipp Dietz、Tobias Lucas、Jonathan Groß、Sebastian Seitel、Jan Brauer、Dorota Ferenc、B. Frank Gupton、Till Opatz

  DOI：10.1021/acs.oprd.1c00139

  日期：2021.8.20

  A short and practical synthesis for preparing the active pharmaceutical ingredient dolutegravir sodium was developed. The convergent strategy starts from (R)-3-amino-1-butanol and establishes the BC ring system in a 76% isolated yield over four steps. Ring A was constructed by a one-pot 1,4-addition to diethyl-(2E/Z)-2-(ethoxymethylidene)-3-oxobutandioate and subsequent MgBr2·OEt2-mediated regioselective

  开发了一种用于制备活性药物成分多替拉韦钠的简短实用的合成方法。收敛策略从 ( R )-3-氨基-1-丁醇开始，并在四个步骤中以 76% 的分离产率建立了 BC 环系统。通过一锅1,4-加成到二乙基-( 2E / Z )-2-(乙氧基亚甲基)-3-氧代丁二酸和随后的MgBr 2 ·OEt 2介导的区域选择性环化来构建环A。与 2,4-二氟苄胺形成酰胺是通过游离羧酸或通过相应乙酯的氨解进行的。最终的盐形成通过六个线性步骤以 48-51% 的分离产率（HPLC 纯度为 99.7-99.9%）提供了多替拉韦钠。
• Synthesis of tetrahydroisoquinolines through TiCl4-mediated cyclization and Et3SiH reduction
  作者：Zeyu Shi、Qiong Xiao、Dali Yin

  DOI：10.1016/j.cclet.2019.09.023

  日期：2020.3

  Abstract A versatile and efficient telescoped reaction sequence for the synthesis of tetrahydroisoquinolines (THIQs) is reported that uses TiCl4 to promote cyclization of a benzylaminoacetal derivative and Et3SiH for reduction of the intermediate 4-hydroxy-THIQ. This method is complimentary to the classical Pomeranz-Fritsch and related reactions since it tolerates electron-withdrawing substituents

  摘要报道了一种通用且有效的伸缩反应序列，用于合成四氢异喹啉（THIQs），该序列使用TiCl4促进苄氨基缩醛衍生物的环化反应，并使用Et3SiH还原中间体4-羟基-THIQ。此方法是对经典Pomeranz-Fritsch和相关反应的补充，因为它可以耐受吸电子取代基并允许使用8位取代的THIQ。